Is there a role for TNF-α antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique

Simple item page
dc.contributor.authorDistler J.H.W.
dc.contributor.authorJordan S.
dc.contributor.authorAirò P.
dc.contributor.authorAlegre-Sancho J.J.
dc.contributor.authorAllanore Y.
dc.contributor.authorBalbir Gurman A.
dc.contributor.authorCaporali R.
dc.contributor.authorCaramaschi P.
dc.contributor.authorCarreira P.E.
dc.contributor.authorChizzolini C.
dc.contributor.authorCutolo M.
dc.contributor.authorTuncay Duruöz M.
dc.contributor.authorFarge-Bancel D.
dc.contributor.authorHesselstrand R.
dc.contributor.authorIannone F.
dc.contributor.authorDe Keyser F.
dc.contributor.authorKucharz E.J.
dc.contributor.authorLaunay D.
dc.contributor.authorGarcía De La Peña Lefebvre P.
dc.contributor.authorLukacova O.
dc.contributor.authorMarasini B.
dc.contributor.authorMartinovic D.
dc.contributor.authorMarques Neto J.F.
dc.contributor.authorRadic M.
dc.contributor.authorRednic S.
dc.contributor.authorRiemekasten G.
dc.contributor.authorRovensky J.
dc.contributor.authorSeidel M.F.
dc.contributor.authorSenel S.
dc.contributor.authorSmith V.
dc.contributor.authorSunderkötter C.
dc.contributor.authorTon E.
dc.contributor.authorVan Laar J.M.
dc.contributor.authorMatucci-Cerinic M.
dc.contributor.authorMüller-Ladner U.
dc.contributor.authorDistler O.
dc.date.accessioned2024-07-22T08:20:07Z
dc.date.available2024-07-22T08:20:07Z
dc.date.issued2011
dc.description.abstractObjective: To obtain experiences and expert opinion on treatment of SSc patients with TNF-α antagonists. Methods: An investigation was carried out among the EUSTAR centres into their expertise on use of TNF-α antagonists. Assessment forms on the frequency of TNF-α inhibitor use were distributed to EULAR Scleroderma Trials and Research Group (EUSTAR) centres. Afterwards, a three round Delphi exercise was performed to obtain expert consensus on the use of TNF-α inhibitors in SSc. Results: Seventy-nine centres returned information on use of TNF-α antagonists in SSc patients. A total of 65 patients were treated with TNF-a inhibitors in 14 different centres. Forty-eight of the 65 patients treated with TNF-α inhibitors improved. Improvement was mainly seen in patients with arthritis, whereas the effects on fibrosis varied. In the first round of the subsequent Delphi approach, 71 out of 79 experts stated that they would use TNF-α antagonists in SSc. Arthritis was suggested as an indication for TNFa antagonists by 75% of the experts. However, after the third stage of the Delphi exercise, the acceptance for the off-label use of TNF-a antagonists decreased and 59% recommended that TNF-α antagonists should not be used or only used in clinical trials in SSc patients, while 38% of the experts suggested the use of TNF-a antagonists for arthritis associated with SSc. Conclusions: Most of the experts do not recommend the routine use of TNF-a antagonists in systemic sclerosis. Arthritis might be a potential indication in SSc, although controlled clinical trials with TNF-α antagonists are needed before general recommendations can be given. © Copyright Clinical and Experimental Rheumatology 2011.
dc.identifier.issn1593098X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17994
dc.language.isoEnglish
dc.subjectAnti-Inflammatory Agents
dc.subjectArthritis
dc.subjectConsensus
dc.subjectDelphi Technique
dc.subjectDisease Progression
dc.subjectFibrosis
dc.subjectHumans
dc.subjectImmunologic Factors
dc.subjectInflammation
dc.subjectOff-Label Use
dc.subjectScleroderma, Systemic
dc.subjectTreatment Outcome
dc.subjectTumor Necrosis Factor-alpha
dc.subjecttumor necrosis factor alpha antagonist
dc.subjecttumor necrosis factor inhibitor
dc.subjectunclassified drug
dc.subjectadalimumab
dc.subjectcorticosteroid
dc.subjectetanercept
dc.subjectinfliximab
dc.subjectarthritis
dc.subjectarticle
dc.subjectclinical assessment tool
dc.subjectDelphi study
dc.subjectfibrosis
dc.subjecthuman
dc.subjectlupus vulgaris
dc.subjectmajor clinical study
dc.subjectmedical society
dc.subjectpriority journal
dc.subjectsystemic sclerosis
dc.subjecttreatment outcome
dc.subjecttreatment planning
dc.subjectArticle
dc.subjectcalcinosis
dc.subjectconsensus development
dc.subjectDelphi study
dc.subjectdeterioration
dc.subjectdrug dose reduction
dc.subjectdysphagia
dc.subjectenthesopathy
dc.subjectfatigue
dc.subjectlung alveolitis
dc.subjectlung fibrosis
dc.subjectlupus like syndrome
dc.subjectmorphea
dc.subjectmyositis
dc.subjectoff label drug use
dc.subjectpulmonary hypertension
dc.subjectRaynaud phenomenon
dc.subjecttendinitis
dc.subjecttreatment indication
dc.titleIs there a role for TNF-α antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique
dc.typeArticle

Files

Collections

Scopus Koleksiyonu